NCT05744596

Brief Summary

This prospective multicenter study investigates the added benefit of incisura biopsy to correct identification of patients with high-risk chronic gastritis (OLGA stages III-IV). It compares a biopsy protocol with and without a single incisura biopsy in a non-inferiority design. Anonymized photo and videodocumentation according to institution practices will constitute a databank for lesion recognition, quality improvement, and potential AI development.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
400

participants targeted

Target at P75+ for all trials

Timeline
10mo left

Started Mar 2023

Longer than P75 for all trials

Geographic Reach
2 countries

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress79%
Mar 2023Mar 2027

First Submitted

Initial submission to the registry

February 7, 2023

Completed
20 days until next milestone

First Posted

Study publicly available on registry

February 27, 2023

Completed
24 days until next milestone

Study Start

First participant enrolled

March 23, 2023

Completed
3.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2027

Last Updated

March 9, 2026

Status Verified

January 1, 2026

Enrollment Period

3.7 years

First QC Date

February 7, 2023

Last Update Submit

March 5, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • prevalence of OLGA III-IV

    number of patients with confirmed OLGA III-IV

    at time of enrollment

Secondary Outcomes (1)

  • prevalence of OLGIM III-IV

    at time of enrollment

Study Arms (2)

Incisura biopsy +

this arm has the incisura biopsy scored and added in the OLGA final stage

Other: Incisura biopsy analysis

Incisura biopsy -

this arm only has corpus and antrum biopsies scored for OLGA staging

Interventions

a pathologist blinded to the other biopsies analyzes the biopsy from the incisura

Incisura biopsy +

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All patients over 18 years undergoing upper GI endoscopy are considered eligible for this study, regardless of gender, age or indication.

You may qualify if:

  • indication to perform upper GI endoscopy for diagnosis or surveillance

You may not qualify if:

  • lack of informed consent, previously diagnosed advanced gastric cancer, incomplete endoscopy, surgically altered stomach

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

IPO Porto

Porto, Portugal

RECRUITING

Colentina Clinical Hospital

Bucharest, Bucharest, 021025, Romania

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

gastric mucosa biopsies

MeSH Terms

Conditions

Gastritis, Atrophic

Condition Hierarchy (Ancestors)

GastritisGastroenteritisGastrointestinal DiseasesDigestive System DiseasesStomach Diseases

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

February 7, 2023

First Posted

February 27, 2023

Study Start

March 23, 2023

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

March 1, 2027

Last Updated

March 9, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will share

Anonymized data and images from endoscopy and pathology are shared between participating centers according to the protocol.

Shared Documents
STUDY PROTOCOL, SAP, CSR
Time Frame
The data will be available during the study period, after enrollment of all participants. Possible usage of the anonymized database will be discussed by study investigators.
Access Criteria
reasonable request

Locations